Full-Time

Lead Validation Engineer

Posted on 11/23/2025

Mallinckrodt

Mallinckrodt

1,001-5,000 employees

Specialty pharmaceutical developer, manufacturer, distributor

No salary listed

St. Louis, MO, USA

In Person

Category
Biology & Biotech (2)
,
Requirements
  • Bachelor’s degree in a science/engineering related field is preferable with related technical background
  • Minimum of 10 years’ experience in review/approving validation in a pharmaceutical manufacturing environment
  • Proven personnel and project management history
  • Complete knowledge of pharmaceutical regulations including current GxP, GAMP5, Part 11 and Data Integrity requirements
  • Knowledge of ICH Q7, Q9, and Q11 preferred
Responsibilities
  • Development and execution of documents including but not limited to: FAT, SAT, IQ, OQ, PQ, and PV
  • Review and approval of validation documents including but not limited to: GxP Assessment, Risk Assessment, Part 11/Annex 11 Assessment, Data Integrity Assessments, IQ, OQ, PQ, Summary Reports, URS, FRS, DS and Traceability Matrix
  • Familiar with Development, QA and Production environment terminology and testing strategies
  • Complete equipment periodic review
  • Responsible for change management validation functional review
  • Temperature mapping of controlled environments
  • Development and review of laboratory equipment qualification protocols
  • Development and review of cleaning validation protocols
  • Collection of cleaning samples – swab / rinse, etc. as required
  • Performs validation document review and approval
  • Responsible for validation procedures, template creation and software validation process improvements
  • Reviews/approves validation deviation investigation
  • Develops validation plans for multiple site implementation
  • Responsible for document management including scanning and archival of validation documents
  • Familiar with data integrity guidance from MHRA and FDA
  • Management of data integrity gap assessments and remediation
  • Performs equipment/system/process level risk assessments per ICH Q9 guidelines
Desired Qualifications
  • Excellent written and oral communication and leadership skills
  • Ability to lead and influence people
  • Ability to work in and promote a team environment
  • Basic understanding of Six Sigma and/or Lean manufacturing tools
  • Complete understanding and application of principles, concepts, practices, and standards within discipline
  • Understanding of basic statistical principles, expert knowledge of validation principles, techniques, and regulatory expectations
  • Knowledge of US and International pharmaceutical manufacturing regulations
  • Experience using thermometric studies instrumentation (Kaye Validator/ValProbes/ Ellab)

Mallinckrodt is a global specialty pharmaceutical company that develops, manufactures, and distributes drugs and therapies for complex and rare conditions, serving healthcare providers, hospitals, and patients mainly in the United States and Europe. Its products target areas such as autoimmune diseases, rare diseases, and critical care, and the business rests on research and development, manufacturing, and sales. The company differentiates itself through a patient-centric approach, a commitment to integrity, ongoing innovation, and collaboration, grounded in more than 150 years of experience and a focus on ESG initiatives. Its goal is to improve the health and well-being of patients worldwide by delivering specialty medicines and advancing sustainable practices.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Hazelwood, Missouri

Founded

1867

Simplify Jobs

Simplify's Take

What believers are saying

  • Merger with Endo completed, forming NYSE-listed therapeutics leader by Q4 2025.
  • Reduced debt 47% to $865.6M and grew Acthar Gel sales 14.2% in 2024.
  • Sold Therakos for $925M, optimizing portfolio for specialty pharmaceuticals.

What critics are saying

  • Endo merger integration disrupts operations, overloading with $6.7B debt.
  • Therakos sale drops immunotherapy revenue, losing edge to Amgen immediately.
  • Acthar Gel's $300K pricing triggers DOJ probe and $500M fines within 18 months.

What makes Mallinckrodt unique

  • Mallinckrodt specializes in Acthar Gel for autoimmune diseases over 150 years.
  • Focuses on rare diseases and critical care therapies for underserved patients.
  • Launched Acthar Gel self-injectable to improve patient adherence and convenience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Relocation Assistance

Company News

PR Newswire
Nov 10th, 2025
Par Health Completes Spin-Off from Mallinckrodt, Creating an Independent Leader in Generic Pharmaceuticals and Sterile Injectables

Launches as Top 15 U.S. Generic Drug Manufacturer, Largest U.S. Producer of Active Pharmaceutical Ingredients and Premier U.S. Producer of Sterile Injectables...

Contract Pharma
Aug 6th, 2025
Mallinckrodt Names Christiana Stamoulis President and CFO

Mallinckrodt plc appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025.

Stock Titan
Aug 1st, 2025
Mallinckrodt-Endo Merger Creates Therapeutics Leader

Mallinckrodt and Endo have completed a merger to form a global therapeutics leader. The companies will combine their generics businesses and Endo's sterile injectables business, which will be spun off as an independent company by Q4 2025. The newly branded company will be listed on the New York Stock Exchange following the spin-off.

The Business Journals
Jul 25th, 2025
Mallinckrodt Reaches $7B Merger Milestone

Mallinckrodt has reached a milestone in a $7 billion merger deal.

Sharecast
Mar 13th, 2025
Mallinckrodt and Endo to merge in $6.7bn deal

Pharmaceutical firm Mallinckrodt said on Thursday that it has agreed to merge with Endo in a $6.7bn deal.

INACTIVE